LYNCHBURG, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bank of the James Financial Group, Inc. (the “Company”) (NASDAQ:BOTJ), the parent company of Bank of the James (the “Bank”), a full-service commercial and retail bank, and Pettyjohn, Wood & White, Inc. (“PWW”), an SEC-registered investment advisor, today announced changes to the Bank’s executive leadership to improve oversight and better coordinate financial and investment approaches. J. Todd Scruggs, currently serving as Chief Financial Officer, will transi ...

Core Points - GlobalFoundries announced the departure of CFO John Hollister for personal reasons, with Sam Franklin appointed as Interim CFO [1][2] - The company expresses confidence in Sam Franklin's ability to manage the transition due to his extensive experience and familiarity with GF's operations [2] - GF's financial results for the upcoming quarter are expected to meet or exceed previous guidance [2] Company Overview - GlobalFoundries is a leading semiconductor manufacturer, providing essential products for various high-growth markets including automotive, smart mobile devices, and communications infrastructure [4] - The company emphasizes innovation and partnerships to deliver high-performance, power-efficient products [4] - GF operates globally with manufacturing facilities in the U.S., Europe, and Asia, focusing on security, longevity, and sustainability [4] Leadership Background - Sam Franklin has over 18 years of experience in corporate finance, investment management, and investment banking, joining GF in 2022 [3] - His previous role included Senior Vice President at Mubadala Investment Company, where he managed financial responsibilities for the Direct Investments group [3]

Core Viewpoint - Huntsman Corporation announced the appointment of Julia Wright as Executive Vice President, General Counsel, and Secretary, effective October 13, 2025, succeeding David Stryker, who will retire at the end of the year [1][3]. Group 1: Leadership Transition - Julia Wright has over 15 years of senior executive experience, previously serving as Senior Vice President, General Counsel, and Secretary at ChampionX Corporation [2]. - David Stryker has been with Huntsman as General Counsel since June 2013 and will assist in the transition while focusing on strategic initiatives [3]. Group 2: Julia Wright's Background - At ChampionX, Wright was responsible for various legal functions, including corporate governance, compliance, and M&A, and played a key role in the company's acquisition by SLB [2]. - Wright's previous experience includes serving as Vice President and General Counsel at Nabors Industries and starting her career at Vinson and Elkins [2]. Group 3: Company Overview - Huntsman Corporation is a global manufacturer and marketer of specialty chemicals, with 2024 revenues of approximately $6 billion [4]. - The company operates over 60 manufacturing and R&D facilities in about 25 countries and employs approximately 6,300 associates [4].

Core Insights - Galapagos NV has appointed Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025, succeeding Mr. Thad Huston, who will assist in the transition until July 31, 2025 [1][2] Group 1: Leadership Transition - Aaron Cox brings over 20 years of experience in biotechnology, capital markets, and M&A, having previously served as CFO at Horizon Therapeutics, where he was instrumental in the company's $28 billion acquisition by Amgen [2] - Cox's role at Galapagos will involve leading Finance, Accounting, Tax, Procurement, Communications, and Investor Relations, and he will be part of the Executive Committee [3] Group 2: Strategic Goals - The CEO of Galapagos expressed confidence in Cox's ability to accelerate pipeline growth through business development and disciplined financial management, aiming to create a new pipeline of innovative medicines [3] - Cox emphasized his excitement to join Galapagos at a pivotal moment, focusing on creating shareholder value and advancing innovations for patients [4] Group 3: Company Overview - Galapagos is a biotechnology company dedicated to transforming patient outcomes through innovative science, with a focus on high unmet medical needs and a commitment to delivering results for patients and shareholders [6]